Castleark Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Castleark Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-77,132	Closed	-$7.3M	–	367
2021 Q1	$7.3M	Buy	77,132 +2,325	+3%	+$276K	0.26%	105
2020 Q4	$9.12M	Sell	74,807 -19,491	-21%	-$2.14M	0.34%	76
2020 Q3	$8.24M	Sell	94,298 -14,749	-14%	-$1.03M	0.32%	92
2020 Q2	$7.04M	Sell	109,047 -970	-0.9%	-$56K	0.31%	94
2020 Q1	$4.91M	Buy	110,017 +44,055	+67%	+$2.34M	0.29%	103
2019 Q4	$4.11M	Sell	65,962 -7,404	-10%	-$352K	0.16%	168
2019 Q3	$2.76M	Buy	+73,366	New	+$3.19M	0.11%	193

Other funds holding TPTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Castleark Management's TPTX Position: Q2 2021 in Review

Castleark Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 77,132 shares — an estimated $7.3M sold.

Castleark Management first reported a position in TPTX in Q3 2019 and held it in 7 quarters. The position peaked at $9.12M in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

Castleark Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Castleark Management sold 77,132 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $7.3M.
Castleark Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Castleark Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $9.12M in Q4 2020.
190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Castleark Management's 13F filing for Q2 2021, filed 17 Aug 2021.